Phaseline

Companies › Definium Therapeutics US

Definium Therapeutics US: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 4 Phase 3, 1 Phase 2; Psychiatry; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DT120
5-HT2A receptor agonist
HTR2APhase 3Major Depressive Disorder; Generalized Anxiety DisorderFeb 2027
Midomafetamine (DT402)
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 2Autism Spectrum DisorderAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06941844DT120Phase 3Major Depressive DisorderPsychiatryFeb 2027
NCT06741228DT120Phase 3Generalized Anxiety DisorderPsychiatryApr 2027
NCT06809595DT120Phase 3Generalized Anxiety DisorderPsychiatryMay 2027
NCT07303907Midomafetamine (DT402)Phase 2Autism Spectrum DisorderPsychiatryAug 2027
NCT07592689DT120Phase 3Major Depressive DisorderPsychiatrySep 2027

From the company's SEC filings

Cash and short-term investments of $1.1bn on 2026-06-30; operating cash outflow about $193m a year; runway about 67 months at that burn, to Feb 2032; 5 of 5 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

HTR2A (1) SLC6A3 (1) SLC6A4 (1) SLC6A2 (1)

Companies with the same targets

Axsome Therapeutics Otsuka Resilient Pharmaceuticals Remedy Intra-Cellular Therapies Currax Pharmaceuticals AlgoTherapeutix Cybin IRL COMPASS Pathways ACADIA Pharmaceuticals

Companies built like this

Remedy Seaport Therapeutics Intra-Cellular Therapies Anavex Life Sciences Cybin IRL

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.